18/12/2025 – AB Science SA announces the initiation of coverage of its stock by Maxim Group, an independent US-based full-service investment bank, securities and wealth management firm Download PDF Post navigationPreviousPrevious post:AB Science announces a new publication on biorxiv that identifies AB8939 as a promising drug candidate for treating refractory acute myeloid leukemia and potentially other cancersNextNext post:AB Science patent for masitinib in the treatment of sickle cell disease formally granted in the US with a protection until 2040Related PostsAB Science patent for masitinib in the treatment of sickle cell disease formally granted in the US with a protection until 204022 December 2025AB Science announces a new publication on biorxiv that identifies AB8939 as a promising drug candidate for treating refractory acute myeloid leukemia and potentially other cancers15 December 2025AB Science announces new publication on Medrxiv highlighting clinical benefit with masitinib in Amyotrophic Lateral Sclerosis patients prior any complete loss of function11 December 2025AB Science announces the successful completion of a 2.8 million euros private placement17 October 2025Summary of the virtual conference held on October 16, 202516 October 2025AB Science webcast of October 16, 202516 October 2025
AB Science patent for masitinib in the treatment of sickle cell disease formally granted in the US with a protection until 204022 December 2025
AB Science announces a new publication on biorxiv that identifies AB8939 as a promising drug candidate for treating refractory acute myeloid leukemia and potentially other cancers15 December 2025
AB Science announces new publication on Medrxiv highlighting clinical benefit with masitinib in Amyotrophic Lateral Sclerosis patients prior any complete loss of function11 December 2025
AB Science announces the successful completion of a 2.8 million euros private placement17 October 2025
